share_log

10-K: Annual report

10-K: Annual report

10-K：年度报表
美股sec公告 ·  04/16 17:11
Moomoo AI 已提取核心信息
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
医疗技术公司SeaStar Medical报告称，截至2023年12月31日的年度净亏损为2620万美元，而上一年的净亏损为1,220万美元，增长了115％。该公司的累计赤字从同比的8,850万美元增至约1.147亿美元。在临床试验费用和工资的推动下，研发费用增长了139％，达到597.3万美元，而由于保险、美国证券交易委员会报告费和法律费用增加，一般和管理费用增长了19％，达到823.7万美元。SeaStar Medical尚未从商业化产品中产生可观的收入，其业务主要通过股权证券、可转换债务和补助金提供资金。截至2023年12月31日，该公司的现金状况约为20万美元，高于去年的0万美元。SeaStar Medical的未来计划包括继续临床开发其选择性细胞移植设备（SCD），以获得美国食品药品管理局的批准并最终实现商业化。但是，该公司承认，需要额外的资本来为运营提供资金，如果有的话，以优惠条件筹集此类资本也存在不确定性。
医疗技术公司SeaStar Medical报告称，截至2023年12月31日的年度净亏损为2620万美元，而上一年的净亏损为1,220万美元，增长了115％。该公司的累计赤字从同比的8,850万美元增至约1.147亿美元。在临床试验费用和工资的推动下，研发费用增长了139％，达到597.3万美元，而由于保险、美国证券交易委员会报告费和法律费用增加，一般和管理费用增长了19％，达到823.7万美元。SeaStar Medical尚未从商业化产品中产生可观的收入，其业务主要通过股权证券、可转换债务和补助金提供资金。截至2023年12月31日，该公司的现金状况约为20万美元，高于去年的0万美元。SeaStar Medical的未来计划包括继续临床开发其选择性细胞移植设备（SCD），以获得美国食品药品管理局的批准并最终实现商业化。但是，该公司承认，需要额外的资本来为运营提供资金，如果有的话，以优惠条件筹集此类资本也存在不确定性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息